177 Lutetium PSMA 617 - Endocyte

Drug Profile

177 Lutetium PSMA 617 - Endocyte

Alternative Names: 177LU-PSMA-617 - Endocyte

Latest Information Update: 09 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Endocyte; RadioMedix
  • Developer Australasian Radiopharmaceutical Trials network; Australian and New Zealand Urogenital and Prostate Cancer Group; Australian Nuclear Science and Technology Organisation; Endocyte; Prostate Cancer Foundation of Australia
  • Class Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action Chelating agents; Glutamate carboxypeptidase II inhibitors; Ionising radiation emitters; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 29 Jan 2018 Phase-II clinical trials in Prostate cancer (Metastatic disease, Hormone refractory) in Australia (IV) (NCT03392428) (ACTRN12617001590358)
  • 06 Nov 2017 Endocyte and Radiomedix entered into agreement for the transfer of the US IND of 177-Lu-PSMA-617
  • 06 Nov 2017 Endocyte, The University of Sydney and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group collaborate for the planned phase II TheraP trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top